Altogether, we identify NSD2 as a novel subunit of the AR <i>neo</i>-enhanceosome that wires prostate cancer gene expression programs, positioning NSD1/2 as viable paralog co-targets in advanced prostate cancer. Here, AR is linked to prostate carcinoma.